Flaxseed ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
97	Ulcerative colitis	1
299	Cystic fibrosis	1

97. Ulcerative colitis

---

Clinical trials : 2,527 /  Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02201758 (ClinicalTrials.gov)	December 2018	18/7/2014	Flaxseed Lignan-Enriched Complex (FLC) for the Treatment of Patients With Ulcerative Colitis (UC): A Pilot Assessment	Flaxseed Lignan-enriched Complex (FLC) for the Treatment of Patients With Mild to Moderately Severe Ulcerative Colitis (UC): A Pilot Assessment.	Ulcerative Colitis	Dietary Supplement: Flaxseed lignan-enriched complex (FLC);Other: Placebo	University of Saskatchewan	Royal University Hospital Foundation	Unknown status	18 Years	N/A	All	56	Phase 2	Canada

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02014181 (ClinicalTrials.gov)	July 2012	27/11/2013	Flaxseed Modulates Inflammation and Oxidative Stress in CF	Flaxseed Modulates Oxidative Stress and Inflammatory Biomarkers in Stable Patients With Cystic Fibrosis and Healthy Controls	Cystic Fibrosis;Oxidative Stress;Inflammation	Dietary Supplement: finely ground flaxseed powder	University of Pennsylvania	NULL	Completed	18 Years	64 Years	Both	10	Phase 1	United States